39 related articles for article (PubMed ID: 32097694)
1. Expression profile of H3K4 demethylases with their clinical and pathological correlation in patients with clear cell renal cell carcinoma.
Kumar A; Kumari N; Nallabelli N; Sharma U; Rai A; Singh SK; Kakkar N; Prasad R
Gene; 2020 May; 739():144498. PubMed ID: 32097694
[TBL] [Abstract][Full Text] [Related]
2. SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization.
Ferreira MJ; Pires-Luís AS; Vieira-Coimbra M; Costa-Pinheiro P; Antunes L; Dias PC; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Epigenetics; 2017; 12(12):1057-1064. PubMed ID: 29099276
[TBL] [Abstract][Full Text] [Related]
3. Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.
Pires-Luís AS; Vieira-Coimbra M; Vieira FQ; Costa-Pinheiro P; Silva-Santos R; Dias PC; Antunes L; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Epigenetics; 2015; 10(11):1033-43. PubMed ID: 26488939
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic Analysis and Clinical Case Studies Identify CD276 as a Promising Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma.
Zhang Z; Xu J; Song Z; Zhang J; Lin Y; Ouyang J
Cancer Control; 2024; 31():10732748241250181. PubMed ID: 38669187
[TBL] [Abstract][Full Text] [Related]
5. High RSK4 expression constitutes a predictor of poor prognosis for patients with clear cell renal carcinoma.
Ma J; Wang K; Chai J; Xu T; Wei J; Liu Y; Wang Y; Xu J; Li M; Fan L
Pathol Res Pract; 2021 Nov; 227():153642. PubMed ID: 34649054
[TBL] [Abstract][Full Text] [Related]
6. The Catalytic-Dependent and -Independent Roles of Lsd1 and Lsd2 Lysine Demethylases in Heterochromatin Formation in
Marayati BF; Tucker JF; Cerda DA; Hou TC; Chen R; Sugiyama T; Pease JB; Zhang K
Cells; 2020 Apr; 9(4):. PubMed ID: 32295063
[TBL] [Abstract][Full Text] [Related]
7. Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.
Bade RM; Schehr JL; Emamekhoo H; Gibbs BK; Rodems TS; Mannino MC; Desotelle JA; Heninger E; Stahlfeld CN; Sperger JM; Singh A; Wolfe SK; Niles DJ; Arafat W; Steinharter JA; Jason Abel E; Beebe DJ; Wei XX; McKay RR; Choueri TK; Lang JM
Mol Oncol; 2021 Sep; 15(9):2330-2344. PubMed ID: 33604999
[TBL] [Abstract][Full Text] [Related]
8. Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.
Arseneault M; Monlong J; Vasudev NS; Laskar RS; Safisamghabadi M; Harnden P; Egevad L; Nourbehesht N; Panichnantakul P; Holcatova I; Brisuda A; Janout V; Kollarova H; Foretova L; Navratilova M; Mates D; Jinga V; Zaridze D; Mukeria A; Jandaghi P; Brennan P; Brazma A; Tost J; Scelo G; Banks RE; Lathrop M; Bourque G; Riazalhosseini Y
Sci Rep; 2017 Mar; 7():44876. PubMed ID: 28332632
[TBL] [Abstract][Full Text] [Related]
9. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.
Turajlic S; Xu H; Litchfield K; Rowan A; Horswell S; Chambers T; O'Brien T; Lopez JI; Watkins TBK; Nicol D; Stares M; Challacombe B; Hazell S; Chandra A; Mitchell TJ; Au L; Eichler-Jonsson C; Jabbar F; Soultati A; Chowdhury S; Rudman S; Lynch J; Fernando A; Stamp G; Nye E; Stewart A; Xing W; Smith JC; Escudero M; Huffman A; Matthews N; Elgar G; Phillimore B; Costa M; Begum S; Ward S; Salm M; Boeing S; Fisher R; Spain L; Navas C; Grönroos E; Hobor S; Sharma S; Aurangzeb I; Lall S; Polson A; Varia M; Horsfield C; Fotiadis N; Pickering L; Schwarz RF; Silva B; Herrero J; Luscombe NM; Jamal-Hanjani M; Rosenthal R; Birkbak NJ; Wilson GA; Pipek O; Ribli D; Krzystanek M; Csabai I; Szallasi Z; Gore M; McGranahan N; Van Loo P; Campbell P; Larkin J; Swanton C;
Cell; 2018 Apr; 173(3):595-610.e11. PubMed ID: 29656894
[TBL] [Abstract][Full Text] [Related]
10. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.
Turajlic S; Xu H; Litchfield K; Rowan A; Chambers T; Lopez JI; Nicol D; O'Brien T; Larkin J; Horswell S; Stares M; Au L; Jamal-Hanjani M; Challacombe B; Chandra A; Hazell S; Eichler-Jonsson C; Soultati A; Chowdhury S; Rudman S; Lynch J; Fernando A; Stamp G; Nye E; Jabbar F; Spain L; Lall S; Guarch R; Falzon M; Proctor I; Pickering L; Gore M; Watkins TBK; Ward S; Stewart A; DiNatale R; Becerra MF; Reznik E; Hsieh JJ; Richmond TA; Mayhew GF; Hill SM; McNally CD; Jones C; Rosenbaum H; Stanislaw S; Burgess DL; Alexander NR; Swanton C; ;
Cell; 2018 Apr; 173(3):581-594.e12. PubMed ID: 29656895
[TBL] [Abstract][Full Text] [Related]
11. Association between CT-based adipose variables, preoperative blood biochemical indicators and pathological T stage of clear cell renal cell carcinoma.
Sun Z; Zhang Y; Xia Y; Ba X; Zheng Q; Liu J; Kuang X; Xie H; Gong P; Shi Y; Mao N; Wang Y; Liu M; Ran C; Wang C; Wang X; Li M; Zhang W; Fang Z; Liu W; Guo H; Ma H; Song Y
Heliyon; 2024 Jan; 10(2):e24456. PubMed ID: 38268833
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of TRUB1 in patients with renal clear cell carcinoma.
Yu QX
Asian J Surg; 2024 Feb; 47(2):1143-1145. PubMed ID: 38030490
[No Abstract] [Full Text] [Related]
13. Sex-Specific Expression of Histone Lysine Demethylases (KDMs) in Thyroid Cancer.
Shobab L; Zheng H; Jensen K; Mendonca-Torres MC; McCoy M; Hoperia V; Rosen J; Wartofsky L; Burman K; Vasko V
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610938
[TBL] [Abstract][Full Text] [Related]
14. Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis.
Dizman N; Lyou Y; Salgia N; Bergerot PG; Hsu J; Enriquez D; Izatt T; Trent JM; Byron S; Pal S
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661119
[TBL] [Abstract][Full Text] [Related]
15. In vitro evidence of NLRP3 inflammasome regulation by histone demethylase LSD2 in renal cancer: a pilot study.
Kumar A; Nallabelli N; Sharma U; Kumari N; Singh SK; Kakkar N; Prasad R
Mol Biol Rep; 2020 Sep; 47(9):7273-7276. PubMed ID: 32754863
[TBL] [Abstract][Full Text] [Related]
16. Specific regulation of BACH1 by the hotspot mutant p53
Su Z; Kon N; Yi J; Zhao H; Zhang W; Tang Q; Li H; Kobayashi H; Li Z; Duan S; Liu Y; Olive KP; Zhang Z; Honig B; Manfredi JJ; Rustgi AK; Gu W
Nat Cancer; 2023 Apr; 4(4):564-581. PubMed ID: 36973430
[TBL] [Abstract][Full Text] [Related]
17. The role of histone methylation in renal cell cancer: an update.
Hou Y; Yuan Y; Li Y; Wang L; Hu J; Liu X
Mol Biol Rep; 2023 Mar; 50(3):2735-2742. PubMed ID: 36575323
[TBL] [Abstract][Full Text] [Related]
18. KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients.
Schäfer G; Bednarova N; Heidenreich A; Klocker H; Heidegger I
Transl Androl Urol; 2021 Oct; 10(10):3946-3952. PubMed ID: 34804837
[TBL] [Abstract][Full Text] [Related]
19. The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.
Angulo JC; Manini C; López JI; Pueyo A; Colás B; Ropero S
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922974
[TBL] [Abstract][Full Text] [Related]
20. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Du C; Lv C; Feng Y; Yu S
J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
